Sanofi said Kevzara - which it produces with partner Regeneron - had failed as a COVID-19 treatment after the latest set of trials in patients across the world showed adverse effects, and would be dropped for studies in this field. Sanofi said the trials had led in some cases to COVID-19 pneumonia infections and even death in a few cases. The two companies do not anticipate conducting further clinical studies of it, Sanofi added. Trials had shown that the drug did not help patients with less severe COVID-19, the companies had said in July. "At Sanofi, we are committed to help combat the global COVID-19 pandemic, including developing vaccine candidates that can be manufactured at large scale," he added.

Source: bd News24 September 01, 2020 07:07 UTC